#### Supplement

Nickl-Jockschat, Ho, Andreasen: "Clinical and neurobiological predictors of long-term outcome in schizophrenia"

#### Methods

#### Patients and Assessments

381 schizophrenia patients (274 males and 107 females) drawn from the Iowa Longitudinal Study (ILS) were included in this study, if they underwent at least 2 years of surveillance. Diagnosis at intake was based on the Comprehensive Assessment of Symptoms and History (CASH), a structured interview developed for longitudinal research (Andreasen et al., 1992). The CASH interview is based on the diagnostic criteria of the Diagnostic and Stastical Manual of Mental Disorders. As recruitment for this cohort started in 1987 and ended in 2007, diagnoses referred to the actual DSM versions at the time of recruitment, i.e., DSM-III and IV. Exclusion criteria for this study included an IQ<70, a history of head trauma and general contraindications for MRI scans. Patients underwent clinical assessments at intake and every 6 months, during which symptom severity and specifity, psychosocial functions and the treatment regimen were documented across the entire timeline of surveillance. Also at intake and and 2, 5, 9, 12, 15 and 18 years after inclusion, patients received a structural MRI (sMRI) scan and an extensive cognitive testing.

## Clinical measures and definitions

We used the well-established three-factor dimensions of positive, negative and disorganized symptoms (Andreasen et al., 1995) to define remission or relapse during the observation period. In detail, we relied upon the following definitions:

*Remission:* a period of time lasting at least 6 months, when none of the following symptoms were rated above 2 (mild) on the SAPS/SANS: delusions, hallucinations, bizarre behavior, positive formal thought disorder, alogia, avolition, and affective flattening. Note that the symptoms of interest do not include the following: anhedonia, attention or inappropriate affect. Brief period of mild symptoms were allowed, if they did not occur longer than 2 weeks and the remission resumed at least for a total of 6 months.

*Psychotic Relapse*: A rating of 4-5 (severe or extreme) on the SAPS/SANS for either hallucinations or delusions lasting continuously for at least 2 weeks.

*Negative Relapse*: A rating of 4-5 (severe or extreme) for at least two of the following: alogia, anhedonia, affective flattening, avolition, or attention lasting continuously for at least 2 weeks.

*Disorganized Relapse*: A rating of 4-5 (severe or extreme) on at least 1 of the following: positive formal thought disorder (PFTD), bizarre behavior, or inappropriate affect lasting continuously for at least 2 weeks.

*General Relapse*: Any period of time when any of the above types of relapse occured. A relapse ended when the symptoms were not rated as severe or extreme (4-5) for at least 4 weeks.

## Structural MRI data acquisition

We used two scanning protocols that we refer to as MR5 and MR6 (Andreasen et al., 2011). Both are multimodal, as they acquire T2 or proton density (PD) sequences apart from T1, to provide optimal discrimination between grey and white matter. Each participant's data included T1-, T2-

, and PD-weighted images collected on a 1.5-T GE Signa scanner for MR5 scanning. MR6 scanning was performed on a 1.5-T Siemens Avanto scanner using T1and T2 sequences. Subjects continued in the same sequence throughout the study. In other words, those who began with an MR5 protocol remained in it for all scans, and those who began with an MR6 protocol remained in it as well. The two sequences differ primarily in slice thickness and in-plane resolution; both are acquired in the coronal plane. Voxel sizes for MR5 are 1.0×1.0×1.5 mm for T1 scans and 1.0×1.0×3 mm for T2 scans; voxel sizes for MR6 are 0.625×0.625×1.5 mm for T1 scans and 0.625×0.625×1.8 mm for T2 scans.

## MRI image analysis

The MRI data sets were analyzed with the AutoWorkup tool (Pierson et al., 2011), a fully automated image processing pipeline that is based on the BRAINS2 software package (Andreasen et al., 1992; Magnotta et al., 2003). In brief, the analysis is composed of four major steps:

- 1) Realignment and coregistration of all scans into the same orientation and resolution
- 2) Tissue classification
- 3) Definition of the borders of the brain and parcellation into subregions and structures
- 4) Measurement of the volumes of brain regions and various tissues within predefined borders

This approach has been optimized for the assessment of brain structural changes in longitudinal samples (Pierson et al., 2011; Andreasen et al., 2013).

Supplementary Table 1

	<b>Remission Only</b>	Mixed	Relapse Only
Sex (M/F)	28/16	118/61	128/30
Age of surveillance (years)	24.01 (SD: 9.125)	24.53 (SD: 6.943)	23.78 (SD: 6.666)
Surveillance Duration Total (years)	7.405 (SD: 4.476)	12.31 (SD: 5.899)	10.68 (SD: 6.322)
Age of Onset (years)	21.59 (SD: 8.157)	21.36 (SD: 6.439)	20.84 (SD: 5.556)
Age first psychotic episode (years)	23.89 (SD: 8.626)	24.00 (SD: 6.628)	23.02 (SD: 5.658)
Age at first medication (years)	24.65 (SD: 9.204)	24.55 (SD: 6.924)	23.94 (SD: 6.686)
Age at first hospitalization (years)	24.57 (SD: 9.584)	24.60 (SD: 6.858)	24.16 (SD: 6.899)
Time between 1 <sup>st</sup> psychotic symptoms and 1 <sup>st</sup> medication (years)	0.626 (SD: 1.523)	0.671 (SD: 2.854)	0.817 (SD: 2.594)

**Supplementary Table 1.** Distribution of demographic characteristics over the three groups (remission only, relapse only and mixed) used in our GLM analyses. The exact criteria that were used to assign patients to one of the groups are depicted in the methods part of the manuscript and in the supplement (above). Please note the distinction between the age at onset (i.e., the manifestation of any clinical symptoms that allow a diagnosis of schizophrenia) and the age at first psychotic episode (i.e., an episode with mainly positive symptoms). SD: standard deviation.

# Supplementary Table 2

	Mean Remission	Mean Relapse	Mean Both	p-value
Cerebral Gray	690.37	700.51	682.95	.1260
Cerebral White	445.21	462.25	444.28	.1664
Cerebral CSF	66.12	73.77	84.14	.0070
Cerebral Tissue	1135.57	1162.76	1127.23	.0072
Frontal Gray	268.54	271.13	264.35	.1185
Frontal White	180.78	187.07	180.67	.3955
Frontal CSF	32.36	36.55	43.16	.0119
Frontal Tissue	449.32	458.20	445.02	.0929
Temporal Gray	161.40	162.66	159.11	.0730
Temporal White	70.78	73.49	70.32	.1797
Temporal CSF	9.32	10.01	10.78	.0283
Temporal Tissue	232.18	236.16	229.43	.0607
Parietal Gray	139.49	141.83	138.46	.6266
Parietal White	104.13	109.80	105.06	.0936
Parietal CSF	12.44	14.12	15.92	.0718
Parietal Tissue	243.62	251.64	243.52	.1727
Occipital Gray	69.69	72.16	69.46	.2621
Occipital White	43.16	45.19	43.84	.9442
Occipital CSF	2.19	2.37	2.45	.7316
Occipital Tissue	112.85	117.35	113.30	.3120
Cortical Gray	640.00	648.85	632.47	.1190
Cortical White	399.20	415.95	400.35	.2319
Cortical CSF	40.98	45.48	52.66	.0317
Cerebellum	132.68	135.98	133.14	.8918
Ventricle/Brain Ratio	.99	1.18	1.39	.0032
Right Putamen	5.50	5.62	5.43	.3813
Left Putamen	5.16	5.32	5.15	.7463
Right Thalamus	6.33	6.25	6.04	.0023
Left Thalamus	6.75	6.71	6.42	.0007
Right Caudate	3.81	3.99	3.87	.4949
Left Caudate	3.77	3.99	3.83	.3021
Right Hippocampus	2.36	2.28	2.23	.0997
Left Hippocampus	2.27	2.24	2.21	.4357
Thalamus	13.08	12.96	12.46	.0008
Putamen	10.65	10.93	10.58	.5547
Caudate	4.64	4.77	4.65	.9751
Hippocampus	4.63	4.52	4.44	.1820

**Supplementary Table 2.** MRI measures across the three groups (remission only, relapse only and mixed) at intake. Shown here are the volumes of all brain regions in our analyses and the p-values for potential differences between the three groups. Significant findings are displayed in bold.

# Supplementary Table 3

	Mean Remission	Mean Relapse	Mean Both	p-value
Cerebral Gray	48	45	27	.2186
Cerebral White	.74	16	20	.0445
Cerebral CSF	.55	6.86	4.04	.0038
Cerebral Tissue	01	35	26	.0158
Frontal Gray	39	62	43	.1197
Frontal White	.62	39	32	.0265
Frontal CSF	1.85	9.17	5.19	.0040
Frontal Tissue	.00	55	40	.0026
Temporal Gray	33	28	19	.8089
Temporal White	.46	.01	04	.8251
Temporal CSF	21	5.76	3.93	.0067
Temporal Tissue	10	21	16	.6897
Parietal Gray	25	57	37	.0635
Parietal White	.60	.03	10	.2508
Parietal CSF	.83	7.54	4.79	.1843
Parietal Tissue	.09	32	27	.0223
Occipital Gray	39	09	.34	.0956
Occipital White	1.05	.23	36	.0790
Occipital CSF	.62	19.27	10.72	.5763
Occipital Tissue	00	02	02	.9498
Cortical Gray	37	47	28	.0924
Cortical White	.61	15	23	.1025
Cortical CSF	2.03	8.32	5.82	.0570
Cerebellum	.18	.02	02	.4796
Ventricle/Brain Ratio	-1.32	4.24	1.86	.0002
Right Putamen	19	.13	.02	.2969
Left Putamen	91	.07	.01	.0254
Right Thalamus	82	45	26	.1310
Left Thalamus	82	83	55	.4111
Right Caudate	30	.11	.03	.2104
Left Caudate	.05	04	.12	.5032
Right Hippocampus	10	.25	.20	.5629
Left Hippocampus	.28	.17	02	.8444
Thalamus	98	60	39	.1098
Putamen	58	.15	.06	.0609
Caudate	61	37	13	.1900
Hippocampus	.08	.18	.08	.9273

**Supplementary Table 3.** Brain volume loss across the three groups (remission only, relapse only and mixed) at intake. Shown here is the change of volume between the first measurement at intake and the last MRI of the study of all brain regions in our analyses and the p-values for potential differences between the three groups. Significant findings are displayed in bold.